Therapeutics targeting the EGFR pathway (gefitinib, cetuximab, and lapatinib) have been some of the most investigated but similarly have demonstrated little efficacy against ACC [19,20,49]. The gene discussed is EGFR; the disease is adrenal cortex carcinoma.